The Next Step After Lab-Made CAR-T
On August 2, 2026, CellOrigin — a China-based biotechnology company focused on next-generation in vivo and in vitro cell therapy — announced two things in one release: solid-tumor cell therapy data from the 2026 ASCO Annual Meeting, and a co-development agreement with Walvax Biotechnology to jointly run an investigator-initiated trial (IIT) of mRNA-LNP-based in vivo GPC3-CAR therapy for hepatocellular carcinoma (HCC), the most common form of liver cancer. BioPharma APAC covered the announcement in full.
The direction matters more than the company size. Every CAR-T therapy approved so far — including China's satri-cel, the world's first solid-tumor CAR-T — is ex vivo: blood is drawn, T cells are engineered in a cleanroom, expanded for weeks, and infused back. In vivo CAR flips that sequence. mRNA wrapped in lipid nanoparticles (mRNA-LNP) is injected and programs the patient's own T cells to attack the tumor from inside the body, the way an mRNA vaccine programs immune memory. No cell factory, no leukapheresis, no weeks of waiting — and, in principle, a fraction of the manufacturing cost.
China is where both generations of this technology are moving fastest. The country has approved more CAR-T products than any other Asian market, hosts the largest pool of CAR-T trial patients, and now has at least two companies — CellOrigin and others — pushing the in vivo format toward the clinic.
What CellOrigin Showed at ASCO 2026
The two solid-tumor programs
At the 2026 ASCO Annual Meeting, the team of CellOrigin's scientific co-founder presented two studies. The first is CAR-Mix, a multicellular synergistic therapy that combines engineered macrophages with polyclonal T cells. In a mesothelin-positive ovarian cancer preclinical model it showed synergistic antitumor activity — the point being to hit antigen heterogeneity, the reason solid tumors escape single-target cell therapy. An IIT based on the product has launched, and the first patient was dosed in early 2026, with initial findings described as a generally well-tolerated safety profile and promising signs of clinical activity.
The second is TMT Engager, an LNP-mRNA-based in vivo T-cell engager that programs the formation of T-cell–macrophage–tumor cell tripartite conjugates in situ. The design deliberately engages both innate and adaptive immunity against multiple tumor antigens, addressing the resistance that tumor heterogeneity drives in current solid-tumor therapies. In preclinical models of both liver cancer and ovarian cancer, the approach produced strong antitumor efficacy. This is the platform CellOrigin says it is building across solid tumors, autoimmune diseases, and organ fibrosis, alongside its other programs — iMAC, CAR-Vac, and the CAR-Mix and TMT Engager platforms just described.
Why GPC3 and Liver Cancer Are the First Target
Hepatocellular carcinoma is the highest-stakes test case for in vivo CAR in Asia. HCC is the dominant liver cancer type, and its incidence is heavily concentrated in East and Southeast Asia, where chronic hepatitis B drives most cases — the same patient populations this site's readers come from. Surgery and local ablation cure early disease, but advanced HCC has historically been a difficult systemic disease, and GPC3 (glypican-3) is one of the most validated tumor-associated antigens in the field: it is highly expressed on HCC cells and largely absent from normal adult tissue, which makes it an ideal CAR target with a wide therapeutic window.
The in vivo GPC3-CAR IIT is based on a preclinical study the same team reported at the 2025 ASCO meeting. In the co-development agreement announced August 2, CellOrigin contributes precision CAR design, early pharmacodynamic evaluation, clinical protocol development, and full-cycle IIT execution, while Walvax — the Yunnan-based vaccine and biologics manufacturer with clinical-grade large-scale capacity and product registration experience — contributes process quality systems, manufacturing, and the regulatory path. The division of labor is the story: a small innovator's design coupled to an industrial partner's ability to make the mRNA-LNP at clinical grade and, eventually, at scale.
CellOrigin's ex vivo sibling in the GPC3 space is worth remembering for context. Oricell's Ori-C101, an ex vivo GPC3 CAR-T for HCC, has been in Chinese trials with striking late-line data, and China's broader solid tumor CAR-T field now spans approved, in-trial, and in-vivo formats. GPC3 is becoming the shared test antigen for every generation of the technology.
Where China's CAR-T Price Picture Stands
The commercial price anchor for cell therapy in China is set by the approved products, and it is already a fraction of US pricing. NMPA-approved CAR-T in China runs roughly $89,000-$151,000 versus $300,000-$500,000 in the United States; satri-cel, the June 2026-approved solid-tumor CAR-T for Claudin18.2-positive gastric cancer, sits at $89,000-$170,000, and Carteyva, the first China-domestic CD19 CAR-T, at $89,000-$120,000. Trial and compassionate-access pricing runs $30,000-$80,000 in China versus $100,000-$200,000 in Western programs.
The in vivo format, if it delivers on its manufacturing logic, sits below both of those bands: mRNA-LNP is a vaccine-style production process, measured in days rather than the weeks required for autologous cell manufacturing, and the product is an off-the-shelf vial rather than a personalized cell batch. That is why the format matters for medical tourism — the cost structure is the access story. Our CAR-T cost guide and clinical trials guide explain the current two-track pricing in detail.
What International Patients Can Access Today
For a patient with advanced HCC, the realistic options in China right now are:
- Trial enrollment — the GPC3 in vivo CAR IIT and the ex vivo GPC3 CAR-T programs (Oricell and others) enroll through major Chinese liver cancer centers. IITs are coordinated directly with the study team and the hospital's international department; pharma-sponsored trials are listed on clinicaltrials.gov. This is the only route to the in vivo program today.
- Approved cell therapy — for patients whose cancer fits the label, satri-cel is commercially available in China for Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction cancer after two prior lines — the world's first approved solid-tumor CAR-T, at $89,000-$170,000.
- Standard liver cancer care — surgery, ablation, TACE, and systemic therapy at Chinese hepatobiliary centers, with the liver treatment guide covering the hospital options and the CAR-T hospital guide explaining how cell therapy is delivered and coordinated.
Patients from Southeast Asia, Russia and Central Asia, and the Middle East — the site's core audiences — are already the majority of international CAR-T patients at Chinese centers, and the pathway is the same one used for the approved products: a referral through an international department, a review of records and pathology, and a treatment plan with an itemized cost estimate before travel. Our cancer treatment guide walks through the full pathway.
The China-Specific Extra: Integrated Supportive Care
Chinese liver cancer centers add a layer that most Western programs do not: integrated Chinese-Western medicine (中西医结合) running alongside the oncology protocol. During and after cell therapy or systemic treatment, Chinese teams routinely add acupuncture for nausea and chemotherapy-induced peripheral neuropathy, herbal formulas to manage fatigue, appetite loss, and ascites-related discomfort, and post-treatment recovery protocols — adjunctive symptom management delivered inside the same hospital by the same care team. It is not alternative treatment standing in for the regimen; it is supportive care layered on top of it, and for a patient facing months of treatment for advanced HCC the difference in day-to-day tolerance is measurable. Our integrated Chinese-Western medicine guide and the TCM in China guide explain how these services are booked and what they cost.
What to Watch Next
Three signals over the next 12-18 months: the first readouts from the CAR-Mix IIT in ovarian cancer (safety already described as well-tolerated, activity to be quantified); dosing in the Walvax co-developed GPC3 in vivo CAR IIT for HCC; and whether the format attracts a global licensing deal — the pattern China's cell therapy field has already established with ex vivo products, where China-first development and world-class data have repeatedly preceded global expansion, as the ivonescimab story shows in antibodies and the senaparib licensing deal showed in small molecules.
The bottom line: China's cell therapy field has moved from lab-made CAR-T — approved, priced at $89,000-$170,000, and already treating international patients — to in vivo CAR, where mRNA-LNP programs a patient's own T cells inside the body. The GPC3 program for liver cancer is the first big test, and it pairs a small innovator (CellOrigin) with an industrial manufacturer (Walvax) in the same two-track pattern that made China's ex vivo CAR-T the world's price reference. Trial enrollment is the access route today; if the format works, the manufacturing math suggests the next generation of cell therapy will be dramatically cheaper — and China will be where it was proven.